

27 Dec 2017 | News

QUOTED. Dec. 27, 2017. Michael Mussallem.

by

Check out what Edwards Lifesciences CEO Michael Mussallem has to say about why it's important for his company to address the needs of patients who rely on transcatheter aortic valve replacement (TAVR) systems.

"We are aggressively pursuing a whole toolbox of therapies for mitral and tricuspid therapies. This is a group of patients that's underserved. They just don't have great answers today. And even though it's not clear that we have all the answers, we're optimistic about it, that some of this is underpinned by our success in TAVR, some of it is just because of the enthusiasm we feel from the clinical community, but we're as optimistic as ever about the opportunity here and we're excited about the challenges ahead and what we might be able to do to tackle those." – Michael Mussallem, CEO, Edwards Lifesciences

> Find out more: [Edwards Adds To Wide Range Of Approaches To Mitral Repair](#)

[Click here](#) for a free trial of *Medtech Insight*